



[19] Rote Liste 2006 [20].
 — Rote Liste 1997

[12], 2005 — Pharmindex 2001
 2009 [2]

1997 29 3
 9 5 34.
 2006 1 2.
 1 2,
 (35%),
 (4%),
 30%,
 9
 Melisal, Melissed,



1.
 (Rote Liste 1997): • — ; • — ; • — ;
 • — ; • —




2.
 (Rote Liste 2006): • — ; • — ; • — ;
 • — ; • —

Nervomix, Perfocrat, Psychotonisol
 4
 (Deprim, Derhip, Intractum Hypericum, Turineurin Hypericum)

3.
 3,
 (67%),
 (33%).

(4 : ,
 , ,)
 (, ,).
 33%, — 17%.


1.
 17 1,
 ()
 4 5.
 4,
 (97%) 3%
 (76%).



3.
 (Pharmindex 2001): • — ;
 • — ; • —


2008/2009

/			
1.		25 , 50 / . 25 , 2 , 10	Egis,
2.		. / 10 , 20, 100	Sandoz,
3.		. / 20 , . . 10 . / 20 , . . 30	,
4.		. / 20 , 30 , 30	Gedeon Richter
5.		. / 50 , 100 , 28	Pfizer Inc.,
6.		. / 50 , 100 , 28	Ranbaxy,
7.	®	. / 50 , 30 . / 100 , 14 . / 100 , 28	Egis,
8.		. / 50 , 20 . / 100 , 20	,
9.	®	. / 50 , 15, 30, 60	Solvay Pharmaceuticals
10.		. / . 50 , 20 . / . 100 , 20	Sandoz,
11.		. / 15 , 30 , 45 20	Sandoz,
12.		. / . 15 , 20 . / . 30 , 20 . / . 45 , 10, 20, 50	,
13.		. / 30 , 10, 30 . / 45 , 30	Schering-Plough,
14.		. / 12,5 , 30	Servier,
15.	®	. 25 , 10, 20, 30, 60 . 37,5 , 14 . 37,5 , 28 . 37,5 , 56 . 50 , 10, 20, 30, 60 ^ . 37,5 , 28 ^ . 37,5 , 30 ^ . 75 , 28 ^ . 75 , 30 ^ . 150 , 28 ^ . 150 , 30	Egis,
16.		, 30,60	n r G,
17.		. / 25 , 14, 28, 56	Servier,
18.		. / 25 , 50 , 50	,



. 4.

(2008/2009): • — ; • —



. 5.

; • — ; • — ; • — ; • —

7
(. 2).

/				
1.			. 10, 30 . 10, 30 . 100	T v ,
2.		6 2	. . 100 , 200	,
3.			. 60? . 20	Sandoz,
4.			30, 60	n r G,
5	®		. / 300 30 . / 300 , 60	,
6			. / . 60 , 10 . / . 60 , 30	,
7			. / 300 , 20 . / 300 , 40	Schwabe,

- 3. 17 -
).

, -
- , 97%

4.

1. , - ; 4
, , (, -

- ,), —

2. - ().
-

,

-

.

-

1. . . - 3. . .
(L.
)// . -
. - 1975. - . 75, 8. - . 1211-1217. . - , 2002. - 37 .

2. 2008/2009 - 4. . . -
(2)/ . . . - : // . . . -
, 2008. - 2270 . 1997. - . 43, 6. - . 494-503.

5. [No authors listed] Final report on the safety assessment of *Hypericum perforatum* extract and *Hypericum perforatum* oil // *Int. J. Toxicol.* - 2001. - Vol. 20, Suppl. 2. - P. 31-39.
6. Amsterdam J.D. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder // *J. Clin. Psychiatry.* - 2003. - Vol. 64, N 2. - P. 208-214.
7. Butterweck V. Mechanism of action of St John's wort in depression: what is known? // *CNS Drugs.* - 2003. - Vol. 17, N 8. - P. 539-562.
8. Degner D., Grohmann R., Kropp S., Riither E., Bender S., Engel R.R., Schmidt L.G. Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP // *Pharmacopsychiatry.* - 2004. - Vol. 37, Suppl. 1. - P. 39-45.
9. Denke A., Schneider W., Elstner E.F. Biochemical activities of extracts from *Hypericum perforatum* L. 2nd Communication: inhibition of met-enkephaline- and tyrosine-dimerization // *Arzneimittelforschung.* - 1999. - Vol. 49, N 2. - P. 109-114.
10. Gallagher D.A., Schrag A. Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease // *CNS Drugs.* - 2008. - Vol. 22, N 7. - P. 563-586.
11. Hauner H. Current pharmacological approaches to the treatment of obesity // *Int. J. Obes. Relat. Metab. Disord.* - 2001. - Vol. 25, Suppl. 1. - P. 102-106.
12. <http://www.pharmindex.pl/baza/>
13. Kleber E., Obry T., Hippeli S. et al. Biochemical activities of extracts from *Hypericum perforatum* L. 1st Communication: inhibition of dopamine-beta-hydroxylase // *Arzneimittelforschung.* - 1999. - Vol. 49, N 2. - P. 106-109.
14. Linde K., ter Riet G., Hondras M. et al. Systematic reviews of complementary therapies an annotated bibliography. Part 2: herbal medicine // *BMC Complement. Altern. Med.* - 2001. - Vol. 1, P. 25.
15. Loo H. [Therapeutic implications of the biochemical features about depressive illness (author's transl)] // *Encephale.* - 1981. - Vol. 7, Suppl. 4. - P. 429-440.
16. Magyar K., Szende B., Lengyel J., Tekes K. The pharmacology of B-type selective monoamine oxidase inhibitors; milestones in (-)-deprenyl research // *J. Neural. Transm.* - 1996. - Vol. 48, Suppl. - P. 29-43.
17. Mauri P., Pietta P. High performance liquid chromatography/electrospray mass spectrometry of *Hypericum perforatum* extracts // *Rapid. Commun. Mass Spectrom.* - 2000. - Vol. 14, 2. - P. 95-99.
18. Petit M., Dollfus S. [Biochemical factors of resistance to antidepressants] // *Encephale.* - 1986. - Vol. 12, Spec No. - P. 207-215.
19. Rote Liste 1997. Berlin: Editio Cantor Verlag, 1997 http://openlibrary.Org/b/OL12981635M/Rote_Liste_1997.
20. Rote Liste 2006. Berlin: Editio Cantor Verlag, 2006. http://openlibrary.Org/b/OL12347063M/Rote_Liste_2006
21. Schempp C.M., Winghofer B., Langheinrich M. et al. Hypericin levels in human serum and interstitial skin blister fluid after oral single-dose and steady-state administration of *Hypericum perforatum* extract (St. John's wort) // *Skin Pharmacol. Appl. Skin Physiol.* - 1999. - Vol. 12, N 5. - P. 299-304.
22. Thiele B., Brink I., Ploch M. Modulation of cytokine expression by hypericum extract // *J. Geriatr. Psychiatry Neurol.* - 1994. - Vol. 7, Suppl. 1. - P. 60-62.
23. Van Praag H.M., Asnis G.M., Kahn R.S. et al. Nosological tunnel vision in biological psychiatry. A plea for a functional psychopathology // *Ann. N.-Y. Acad. Sci.* - 1990. - Vol. 600. - P. 501-510.
24. Wurglics M., Westerhoff K., Kaunzinger A. et al. Batch-to-batch reproducibility of St. John's wort preparations // *Pharmacopsychiatry.* - 2001. - Vol. 34, Suppl 1. - P. 152-156.
25. Yanagisawa N. [Clinical characteristics and trends in research of Parkinson's disease and parkinsonism in Japan] // *Nippon Rinsho.* - 1997. - Vol. 55, N 1. - P. 9-15.

13.01.2010

615.214.32:615.322:615.011:633.88:581.19

17

97%

E.Yu. Konovalova, T.K. Shurajeva, T.B. D, T.A. Groshoviy, N.P. Darzuli

ANALYSIS OF MARKET OF ANTIDEPRESSANT PREPARATIONS FROM ST-JOHN'S WORT (HYPERICUM PERFORATUM L.) REGISTERED IN UKRAINE

Key words: plant antidepressants, analysis of market, *Hypericum perforatum* L.

The results of market analysis of antidepressant preparations from St-john's wort (*Hypericum perforatum* L.) registered in Ukraine are presented in the article. The comparative analysis of correlation of antidepressants' medicinal forms on German and Russian markets is conducted, it is shown that pills are optimal medicinal form of antidepressant preparations from *Hypericum perforatum*. 17 names of the antidepressant preparations of synthetic origin are counted in the market of Ukraine, 97% from which are preparations of foreign production. Plant antidepressants in the market of Ukraine are presented only one preparation (*Helarium hypericum*) of foreign production. It testifies about the expedience of creation of the domestic antidepressant preparation on the basis of dry extract of *Hypericum perforatum* in medicinal form 'pills'.

: 615.322:615.19:615.074

B.A.

 $B^{\wedge}.$

FUMARIA OFFICINALIS L.
FUMARIA SHLEICHERI SOY.-WILLEM.

lis L.)

(Fumaria officina-

Soy.-Willem.),

(Fumaria

parviflora Lam.),

(Fumaria

- rostellata Knaf.)

(Fumaria

- kralikii Jord.) [3].

F.shleicheri

- Soy.-Willem.

[2].

F. officinalis L.,

Loisel.),

(Fumaria vaillantii

(Fumaria shleicheri

(2007-2009)